T THERAVANCE BIOPHARMA INC
| Market Cap | $704.60M |
| P/E Ratio | 24.39 |
| Forward P/E | 6.33 |
| Dividend Yield | — |
| Beta | 0.11 |
| 52W Range | $7.90 - $21.03 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 13 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sale | 7,766 | $13.92 | $108.07K | 16 Mar 2026 | 16 Mar 2026 |
| Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sale | 15,534 | $14.00 | $217.48K | 16 Mar 2026 | 16 Mar 2026 |
| Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sale | 7,767 | $13.92 | $108.09K | 16 Mar 2026 | 16 Mar 2026 |
| Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sale | 7,766 | $18.75 | $145.62K | 03 Dec 2025 | 05 Dec 2025 |
| Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sale | 15,534 | $18.75 | $291.25K | 03 Dec 2025 | 05 Dec 2025 |
| Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sale | 7,767 | $18.75 | $145.63K | 03 Dec 2025 | 05 Dec 2025 |
| BROSHY ERAN | Sale | 15,501 | $20.00 | $310.02K | 26 Nov 2025 | 01 Dec 2025 |
| BROSHY ERAN | Sale | 14,000 | $20.00 | $280.00K | 26 Nov 2025 | 01 Dec 2025 |
| Eran BroshyDirector | Sale | 15,501 | $20.00 | $310.02K | 26 Nov 2025 | 01 Dec 2025 |
| Eran BroshyDirector | Sale | 14,000 | $20.00 | $280.00K | 26 Nov 2025 | 01 Dec 2025 |
| BROSHY ERAN | Sale | 29,500 | $18.50 | $545.75K | 11 Nov 2025 | 13 Nov 2025 |
| BROSHY ERAN | Sale | 14,000 | $18.50 | $259.00K | 11 Nov 2025 | 13 Nov 2025 |
| BROSHY ERAN | Sale | 15,500 | $17.00 | $263.50K | 11 Nov 2025 | 13 Nov 2025 |
Frequently Asked Questions
What is TBPH stock price today?
THERAVANCE BIOPHARMA INC (TBPH) is currently trading at $13.91. The stock has a 52-week range of $7.90 to $21.03 and a market capitalization of $704.60M.
Is TBPH a good stock to buy in 2026?
THERAVANCE BIOPHARMA INC has a P/E ratio of 24.4 (forward P/E: 6.3), a dividend yield of none, and 1-year performance of +47.3%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling TBPH stock?
There have been 13 insider transactions for TBPH in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has TBPH stock performed over the past year?
THERAVANCE BIOPHARMA INC (TBPH) has returned +47.3% over the past 12 months. The stock traded between $7.90 and $21.03 during this period, and is currently at $13.91.
Which hedge funds own TBPH (THERAVANCE BIOPHARMA INC)?
0 tracked hedge funds currently hold TBPH in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is TBPH's market cap and valuation?
THERAVANCE BIOPHARMA INC (TBPH) has a market capitalization of $704.60M. The trailing P/E ratio is 24.4 and forward P/E is 6.3. The stock is classified in the Healthcare sector.
What is TBPH's revenue and profitability?
THERAVANCE BIOPHARMA INC reported revenue of $80.33M with net income of $29.34M and a profit margin of 0.37%. The stock has a beta of 0.11.
What sector is TBPH in and who are its biggest institutional holders?
THERAVANCE BIOPHARMA INC (TBPH) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.